UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 121

Sortiert nach

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

Annals of oncology, 2019-03, Vol.30 (3), p.418-423

2019

Volltextzugriff (PDF)

Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review

The international journal of biochemistry & cell biology, 2016-08, Vol.77 (Pt A), p.91-101

2016

Volltextzugriff (PDF)

Post-traumatic Growth in the Italian Experience of Long-term Disease-free Cancer Survivors

Stress and health, 2015-08, Vol.31 (3), p.189-196

2015

Volltextzugriff (PDF)

A Gradient-Based Approach for Breast DCE-MRI Analysis

BioMed research international, 2018-01, Vol.2018, p.9032408-10

2018

Volltextzugriff (PDF)

Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer

European journal of human genetics : EJHG, 2013-08, Vol.21 (8), p.824-830

2013

Volltextzugriff (PDF)

9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Annals of oncology, 2018-10, Vol.29, p.viii705-viii705

2018

Volltextzugriff (PDF)

1899 Correlation between Ki-67 and FISH testing of HER2 IHC 1+ early invasive breast cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S299-S299

2015

Volltextzugriff (PDF)

Nuclear NHERF1 expression as a prognostic marker in breast cancer

Cell death & disease, 2013-11, Vol.4 (11), p.e904-e904

2013

Volltextzugriff (PDF)

Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Annals of oncology, 2018-10, Vol.29, p.viii58-viii59

2018

Volltextzugriff (PDF)

Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

Annals of oncology, 2017-10, Vol.28, p.vi1-vi1

2017

Volltextzugriff (PDF)

Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study

International journal of oncology, 2014-11, Vol.45 (5), p.2137-2142

2014

Volltextzugriff (PDF)

1857 Final results of a phase II study evaluating oral vinorelbine as a single-agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NorBreast-228 trial)

European journal of cancer (1990), 2015-09, Vol.51, p.S284-S284

2015

Volltextzugriff (PDF)

40P A survey on smoking and tobacco control perceptions from physicians and employees working in an Italian cancer center

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S72-S72

2016

Volltextzugriff (PDF)

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study

Annals of oncology, 2012-05, Vol.23 (5), p.1121-1129

2012

Volltextzugriff (PDF)

312 TROP-2 Expression and Mutation in Familiar Breast Cancer

European journal of cancer (1990), 2012-03, Vol.48, p.S133-S133

2012

Volltextzugriff (PDF)

234 Metastatic Breast Cancer – a Retrospective Analysis of Abdominal/pelvic Metastasis of Breast Origin

European journal of cancer (1990), 2012-03, Vol.48, p.S111-S111

2012

Volltextzugriff (PDF)

313 HER-2/neu Overexpression as Prognostic Factor in Small Size Breast Cancer (pT1, N0, M0)

European journal of cancer (1990), 2012-03, Vol.48, p.S134-S134

2012

Volltextzugriff (PDF)

412P Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes

Annals of oncology, 2023-10, Vol.34, p.S356-S356

2023

Volltextzugriff (PDF)

PO-38: A new armamentarium choice in cancer-associated upper-limb vein thrombosis resistant to heparin: a clinical case of seminoma in BEP chemotherapy protocol solved with edoxaban

Thrombosis research, 2022-05, Vol.213, p.S28-S29

2022

Volltextzugriff (PDF)

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Annals of oncology, 2018-12, Vol.29 (12), p.2328-2333

2018

Volltextzugriff (PDF)

A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study

Oncology, 2011-01, Vol.81 (3-4), p.230-236

2011

Volltextzugriff (PDF)

Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study

Annals of oncology, 2007-06, Vol.18 (suppl-6), p.vi66-vi69

2007

Volltextzugriff (PDF)

27 HER2/NEU OVEREXPRESSION IN pT1a OR pT1b, N0,M0 BREAST CANCER

Cancer treatment reviews, 2010, Vol.36, p.S103-S103

2010

Volltextzugriff (PDF)

478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study

Annals of oncology, 2023-10, Vol.34, p.S382-S382

2023

Volltextzugriff (PDF)

41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial

Annals of oncology, 2021-05, Vol.32, p.S37

2021

Volltextzugriff (PDF)

1 – 25 von 121

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(119)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(47)
Humans
(41)
Female
(35)
Middle Aged
(33)
Adult
(29)
Oncology
(29)
Aged
(28)
Biological And Medical Sciences
(23)
Medical Sciences
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(19)
Male
(17)
Breast Neoplasms - Drug Therapy
(14)
Pharmacology. Drug Treatments
(14)
Breast Cancer
(13)
Chemotherapy
(12)
Antineoplastic Agents
(11)
Breast Neoplasms - Pathology
(10)
Tumors
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review

Post-traumatic Growth in the Italian Experience of Long-term Disease-free Cancer Survivors

A Gradient-Based Approach for Breast DCE-MRI Analysis

Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer

9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

1899 Correlation between Ki-67 and FISH testing of HER2 IHC 1+ early invasive breast cancer

Nuclear NHERF1 expression as a prognostic marker in breast cancer

Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study

1857 Final results of a phase II study evaluating oral vinorelbine as a single-agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NorBreast-228 trial)

40P A survey on smoking and tobacco control perceptions from physicians and employees working in an Italian cancer center

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study

312 TROP-2 Expression and Mutation in Familiar Breast Cancer

234 Metastatic Breast Cancer – a Retrospective Analysis of Abdominal/pelvic Metastasis of Breast Origin

313 HER-2/neu Overexpression as Prognostic Factor in Small Size Breast Cancer (pT1, N0, M0)

412P Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes

PO-38: A new armamentarium choice in cancer-associated upper-limb vein thrombosis resistant to heparin: a clinical case of seminoma in BEP chemotherapy protocol solved with edoxaban

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study

Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study

27 HER2/NEU OVEREXPRESSION IN pT1a OR pT1b, N0,M0 BREAST CANCER

478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study

41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial

Suchergebnisse filtern